CSTONE PHARMACEUTICALS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9 HKD | 0.00% |
|
+5.88% | -60.35% |
| Apr. 24 | Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% | MT |
| Apr. 23 | CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,322 | 9,760 | 7,847 | 4,875 | 2,629 | 1,061 | - | - |
| Enterprise Value (EV) 1 | 6,607 | 6,792 | 7,250 | 4,544 | 2,629 | 440 | 598.4 | 189.4 |
| P/E ratio | -3.85 x | -7.25 x | - | -5.31 x | -7.11 x | -2.16 x | -6.17 x | 11.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 9.4 x | 32.2 x | 10.1 x | 5.67 x | 1.26 x | 1.09 x | 0.9 x |
| EV / Revenue | - | 6.54 x | 29.7 x | 9.44 x | 5.67 x | 0.52 x | 0.61 x | 0.16 x |
| EV / EBITDA | -4.02 x | -6.31 x | -3.99 x | -5.09 x | -4.49 x | -1.04 x | -3.53 x | 1.71 x |
| EV / FCF | -6,078,351 x | -11,810,660 x | -4,570,514 x | -7,418,360 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 3.58 x | 3 x | 6.63 x | 10.9 x | - | 1.16 x | 1.7 x | - |
| Nbr of stocks (in thousands) | 1,012,681 | 1,150,415 | 1,164,452 | 1,192,099 | 1,274,056 | 1,274,084 | - | - |
| Reference price 2 | 9.205 | 8.484 | 6.738 | 4.089 | 2.063 | 0.8331 | 0.8331 | 0.8331 |
| Announcement Date | 3/26/20 | 3/25/21 | 6/8/22 | 4/26/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,039 | 243.7 | 481.4 | 463.8 | 844.5 | 978.1 | 1,186 |
| EBITDA 1 | -1,642 | -1,077 | -1,818 | -892.9 | -585.4 | -421.1 | -169.3 | 110.5 |
| EBIT 1 | -1,653 | -1,092 | -1,829 | -912.1 | -605.6 | -462.1 | -212.2 | 79.24 |
| Operating Margin | - | -105.11% | -750.64% | -189.49% | -130.55% | -54.72% | -21.7% | 6.68% |
| Earnings before Tax (EBT) 1 | -2,308 | -1,221 | -1,920 | -902.7 | -367.2 | -454.2 | -176.9 | 104.8 |
| Net income 1 | -2,308 | -1,221 | -1,920 | -902.7 | -367.2 | -454.2 | -158.6 | 89.06 |
| Net margin | - | -117.54% | -787.84% | -187.53% | -79.17% | -53.78% | -16.21% | 7.51% |
| EPS 2 | -2.390 | -1.170 | - | -0.7700 | -0.2900 | -0.3850 | -0.1350 | 0.0700 |
| Free Cash Flow | -1,087 | -575.1 | -1,586 | -612.5 | - | - | - | - |
| FCF margin | - | -55.36% | -650.9% | -127.24% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/25/21 | 6/8/22 | 4/26/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1,039 | 79.4 | 164.3 | 261.8 | 219.6 | 261.5 | 202.4 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | -704 | -1,125 | -209.7 | -533.4 | -254 | -351.6 | - | - |
| Operating Margin | - | - | - | - | -886.62% | -685.14% | -80.11% | -242.89% | -97.13% | -173.74% | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | -0.3100 | -0.4600 | -0.1700 | -0.1200 | -0.1000 | 0.0600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/14/19 | 3/26/20 | 8/18/20 | 3/25/21 | 8/26/21 | 6/8/22 | 9/23/22 | 4/26/23 | 8/15/23 | 4/23/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 2,715 | 2,968 | 596 | 331 | - | 621 | 463 | 872 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -1,087 | -575 | -1,586 | -612 | - | - | - | - |
| ROE (net income / shareholders' equity) | -154% | -44.9% | -92.3% | -109% | - | -216% | -37.9% | - |
| ROA (Net income/ Total Assets) | -101% | -36.4% | - | - | - | - | - | - |
| Assets 1 | 2,289 | 3,357 | - | - | - | - | - | - |
| Book Value Per Share 2 | 2.570 | 2.820 | 1.020 | 0.3700 | - | 0.7200 | 0.4900 | - |
| Cash Flow per Share | - | -0.4900 | -1.280 | - | - | - | - | - |
| Capex | 6.21 | 67 | 91 | - | - | - | - | - |
| Capex / Sales | - | 6.45% | 37.35% | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/25/21 | 6/8/22 | 4/26/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8331
CNY
Average target price
3.186
CNY
Spread / Average Target
+282.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.35% | 146M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2616 Stock
- Financials CStone Pharmaceuticals
